Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

68.28
11,965,096

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Stock Market News for Apr 12, 2021

Benchmarks hit record levels on Friday, closing in the green for consecutive weeks as investors shrugged off inflation fears and focused on quarterly earnings season amid reopening optimism

J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots

The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.

Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study

Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.

ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data

ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.

Higher-Than-Expected PPI in March

Higher-Than-Expected PPI in March.

Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study

Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.

Mark Vickery headshot

PPI Doubles Month Over Month to 1.0%

We haven't seen a higher headline PPI figure since the fallout of the pandemic era, now more than a year ago.

Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study

Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots

European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.

Earnings Estimates Rising for Moderna (MRNA): Will It Gain?

Moderna (MRNA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study

Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.

Company News for Apr 7, 2021

Companies in The News Are: ILMN, NVAX, MRNA, BP.

Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

Rimmi Singhi headshot

5 Stocks With High Earnings Yield for Superior Returns

Check out high earnings yield stocks including AA, USAK, GIII, MU and MRNA for a standout portfolio.

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies

Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Moderna (MRNA) closed the most recent trading day at $132.55, moving +1.22% from the previous trading session.

The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna

The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna

Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens

Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.

Sweta Jaiswal, FRM headshot

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Sheraz Mian headshot

Top Research Reports for Comcast, Netflix & PepsiCo

Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Netflix,Inc. (NFLX) and PepsiCo, Inc. (PEP).

Sweta Jaiswal, FRM headshot

Moderna ETFs to Gain on Positive 'Real-World' Study Data

Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.

Sweta Jaiswal, FRM headshot

Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth

J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.